Thirteen studies that evaluated the effects of anti‐PD‐1/PD‐L1 therapy for HCC on clinical responses or survival by PD‐L1 status were ultimately included in the qualitative analysis.5, 6, 7, 9, 10, 11, 21, 22, 23, 24, 25, 26, 27. This evidence concerns the gene CD274 and hepatocellular carcinoma.